Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Acrocephalosyndactylia 5Cholangiocarcinoma 4Neoplasm Metastasis 3Carcinoma, Transitional Cell 3Recurrence 2Urinary Bladder Neoplasms 1Pancreatic Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Unknown Primary 1Myeloproliferative Disorders 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Liposarcoma 1Leukemia, Myeloid, Acute 1Glioma 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Eosinophilia 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Rituximab 45Cyclophosphamide 32Lenalidomide 24fludarabine 20zanubrutinib 13venetoclax 12obinutuzumab 12orelabrutinib 11fludarabine phosphate 10Bendamustine Hydrochloride 10Magnetic Resonance Spectroscopy 9Whole-Body Irradiation 8Prednisone 8pirtobrutinib 7ibrutinib 7Vincristine 7Specimen Handling 7CT-P10 7Mycophenolic Acid 6Biopsy 6Doxorubicin 5tafasitamab 4pembrolizumab 3acalabrutinib 3Tacrolimus 3Sirolimus 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Nivolumab 3Melphalan 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, B-Cell, Marginal Zone × pemigatinib × 1 year × Clear all
NCT06300528 2025-12-03

Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

University of Utah

Phase 2 Recruiting
27 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡